Tissue plasminogen activator and acute pulmonary embolism
- 1 December 1988
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 38 (4) , 303-312
- https://doi.org/10.1002/jcb.240380409
Abstract
We assessed the efficacy and safety of peripheral intravenous recombinant human tissue‐type plasminogen activator (rt‐PA) in 47 patients with angiographically documented pulmonary embolism (PE). We administered 50 mg/2 h and, if necessary, an additional 40 mg/4 h. By 6 hours, 94% of the patients had angiographic evidence of clot lysis that was slight in 5, moderate in 12, and marked in 27 patients. Among the 34 patients with pulmonary hypertension prior to treatment, average pulmonary artery pressure decreased from 43/17 (27) to 31/13 (19) mm Hg (P < 0.0001). The average lung scan perfusion defect decreased from 37% before therapy to 16% (P < 0.01) after therapy among the 19 patients who had pre‐ and post‐treatment lung scans. Of 7 patients with pre‐ and post‐treatment imaging and Doppler echocardiograms, hypokinetic right ventricular wall movement (mild in 1, moderate in 2, and severe in 4) normalized in 5 and improved to mild hypokinesis in 2. Right ventricular diameter decreased from 3.9 ± 1.0 to 2.0 ± 0.5 cm (P < 0.005). Fibrinogen decreased 33% from baseline at 2 h and 42% from baseline at 6 h. However, patients with the greatest degree of angiographic clot lysis at 2 h had a preponderance of fibrinogenolysis over fibrinolysis, demonstrated by a lower ratio of cross‐linked fibrin degradation products to fibrin(ogen) degradation products (0.14 ± 0.09 vs. 0.54 ± 0.82) (P < 0.04). Among selected patients, peripheral intravenous rt‐PA is associated with rapid lysis of PE, improved pulmonary perfusion, and improved right ventricular function.Keywords
This publication has 21 references indexed in Scilit:
- RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISMThe Lancet, 1988
- Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activatorJournal of the American College of Cardiology, 1987
- Thrombolytic therapy of acute pulmonary embolism: Current status and future potentialJournal of the American College of Cardiology, 1987
- Perspectives on Treatment of Acute Pulmonary Embolism with Tissue Plasminogen ActivatorSeminars in Thrombosis and Hemostasis, 1987
- Coronary thrombolysis with recombinant tissue-type plasminogen activator: Patency rate and regional wall motion after 3 monthsJournal of the American College of Cardiology, 1986
- Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agentsAmerican Heart Journal, 1986
- A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.Circulation, 1985
- Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATIONJournal of Clinical Investigation, 1983
- Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.Journal of Clinical Investigation, 1982
- Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolusNature, 1981